Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter

Executive Summary

Intarcia announced $215m in new equity financing and revised its NDA submission timeline for the second time since it reported positive Phase III results for ITCA 650 versus Januvia in mid-2015.

Advertisement

Related Content

VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross
Biopharma Quarterly Dealmaking Statistics, Q3 2016
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Intarcia's Once-Yearly Diabetes Drug Bests Januvia
Intarcia boosts private cash with $1bn-plus Servier deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel